<DOC>
	<DOC>NCT00362648</DOC>
	<brief_summary>The purpose of the current study is to evaluate whether the vaccine is effective, well-tolerated and immunogenic among infants in developing countries.</brief_summary>
	<brief_title>Developing World Study for RotaTeq™ (V260-015)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<criteria>Age 4 weeks through 12 weeks at Dose 1 Parent able to understand study procedures and give consent Clinical evidence of active gastrointestinal disease Subjects who are currently or expected to participate in other studies of investigational products during the 6 weeks after receiving the last dose of RotaTeq™/placebo</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>